TENX Tenax Therapeutics - Merlintrader Trading Pub

TENXd010632373i — TENX Tenax Therapeutics 4

Tenax Therapeutics (NASDAQ: TENX) — Clinical-stage cardiopulmonary biotech

Executive Summary

Tenax Therapeutics is advancing oral levosimendan (TNX-103) for pulmonary hypertension associated with HFpEF (PH-HFpEF), with a registrational path built around the LEVEL Phase 3 program and a planned second global Phase 3 study (LEVEL-2) described in company materials and FDA-aligned updates.

Timeline guidance has evolved across 2025 updates; this page anchors the timeline to dated company releases and SEC filings (see Primary Sources).

Quick Data (verifiable snapshot)

Item	Verified snapshot (with primary links)
Shares outstanding	6,243,575 shares of common stock outstanding as of Nov 11, 2025, per the Form 10-Q (filed Nov 12, 2025; quarter ended Sep 30, 2025).
Cash & equivalents	$105.5M cash and cash equivalents as of June 30, 2025, per Tenax Q2 2025 results release and the SEC 10-Q (period ended Jun 30, 2025).
Net loss (Q2 2025)	Reported net loss of ~$10.9M for the quarter ended June 30, 2025, per Tenax Q2 2025 results release.
Runway guidance	Company stated expectation that cash and cash equivalents would fund operations through 2027 in the Q2 2025 release. For the formal “liquidity and capital resources” discussion, see the corresponding SEC 10-Q.
Financing (context)	$25M private placement announced Mar 5, 2025: company release and described in the SEC 10-Q (period ended Mar 31, 2025).
Primary value driver	TNX-103 (oral levosimendan) in PH-HFpEF; Phase 3 program and Level/Level-2 positioning described in Mar 5, 2025 company announcement and later corporate updates (see Sources).

Company Overview

Tenax Therapeutics is a development-stage company focused on cardiopulmonary disorders, with oral levosimendan (TNX-103) targeting PH-HFpEF. The near-term valuation narrative is primarily tied to Phase 3 execution and timeline communication in dated SEC filings and official releases.

Pipeline — What matters now vs later

Core program

TNX-103 (PH-HFpEF): Oral levosimendan; Phase 3 program updates include LEVEL expansion and plans to initiate LEVEL-2, per Mar 5, 2025 release and subsequent corporate updates.

Earlier-stage / optionality

Near-term investor attention is dominated by PH-HFpEF until additional assets mature; this report stays anchored to what is disclosed in SEC filings and official IR.

Clinical Data — What is public and verifiable

Phase 3 LEVEL (TNX-103 oral levosimendan in PH-HFpEF)

Program expansion (FDA alignment): company announced an amendment to enlarge LEVEL and increase statistical powering, per Mar 5, 2025 release.
Timeline (as of Aug 13, 2025): Q2 2025 corporate update provides the cash snapshot and corporate context; see Q2 2025 release and the corresponding SEC 10-Q (Jun 30, 2025).
Timeline update (as of Nov 12, 2025): company stated enrollment completion (230 patients) expected in 1H 2026 and topline data expected in 2H 2026, per Q3 2025 release.

Interpretation note: timelines can shift. The only authoritative anchors are the most recent dated SEC filings and official IR/press releases listed in Primary Sources.

Catalysts & What traders will watch

Phase 3 topline

Execution

Watch for analysis set, endpoint hierarchy, safety dataset size and clarity at topline. The latest dated guidance in Q3 2025 materials points to 2H 2026.

Financing cadence

Dilution

Monitor share count on SEC cover pages, offerings, and material financing terms in EDGAR. The March 2025 private placement is described in the SEC 10-Q (period ended Mar 31, 2025).

Expectation resets

Comparables

Cardiopulmonary read-throughs can move sentiment. This page avoids third-party “hype” and anchors to SEC + official IR for facts.

Financial Snapshot (anchored to filings and dated releases)

The cleanest verified anchors in 2025 disclosures are: $105.5M cash and cash equivalents as of June 30, 2025, and a reported net loss ~ $10.9M for Q2 2025 (quarter ended June 30, 2025). Runway commentary in the Q2 release references funding through 2027 (see Primary Sources below).

Metric	Value (verified)	Primary anchor
Cash & cash equivalents	$105.5M (June 30, 2025)	Q2 2025 release • SEC 10-Q (Jun 30, 2025)
Net loss (Q2 2025)	~$10.9M	Q2 2025 release
Shares outstanding (snapshot)	6,243,575 (as of Nov 11, 2025)	Form 10-Q (filed Nov 12, 2025)
Private placement (gross)	$25.0M (March 2025)	Company release • SEC 10-Q (Mar 31, 2025)

Ownership / Short Interest / Insider Activity

This section is intentionally “how-to verify” (not a database snapshot), because ownership and short data can be mismatched across vendors. For primary verification:

Institutional ownership: 13F filings on EDGAR (by quarter).
Insiders: Form 4 filings on EDGAR (dated, with quantities/prices).
Company SEC hub: Tenax SEC filings page.

Practical tip: align the date of the share count (10-Q cover page) with the date of any 13G/13D or short-interest table you are reading.

Sentiment (high-level)

The recurring sentiment clusters around: (1) unmet need framing in PH-HFpEF, (2) financing and dilution expectations vs cash runway, and (3) binary Phase 3 outcomes. This report avoids using social chatter as “evidence” and keeps factual claims anchored to SEC and official releases.

Bull vs Bear Framework (educational, not advice)

Bull case (what would need to be true)

Illustrative

Phase 3 executes cleanly (enrollment, retention, safety dataset).
Efficacy is clinically meaningful with acceptable tolerability.
Regulatory path remains consistent with the company’s described framework in dated disclosures.
Financing remains manageable (track offerings and share count in EDGAR).

Base case (what “normal” could look like)

Illustrative

Volatility persists until topline data are public.
Runway confidence is sensitive to trial cost and pace of enrollment.
Headline-driven swings continue around each dated update.

Bear case (what breaks the story)

Illustrative

Efficacy or safety disappoints (including adherence/retention).
Endpoints or powering do not translate into an approvable package.
Dilution accelerates faster than expected due to burn or capital needs.

Key Risks (plain language)

Clinical risk: Phase 3 outcomes can be binary; tolerability and adherence can matter as much as endpoint results.
Regulatory risk: endpoints, safety database and labeling expectations can evolve; SEC/IR updates are the anchor.
Financial risk: late-stage costs can shift burn materially; track cash flow in 10-Q statements.
Dilution risk: offerings, warrant exercises and share count changes should be monitored through EDGAR.

Bottom Line (what this is, and what it isn’t)

TENX sits at the intersection of high unmet need framing and late-stage binary risk. This page stays anchored to verifiable facts: SEC filings and official company communications. Any framework language is educational and not investment advice.

Chart image source: Finviz (chart image load contains no affiliate parameters). For clickable links, see Tools & Partners below.

Primary Sources (clickable)

SEC 10-Q (quarter ended Jun 30, 2025): EDGAR document
Q2 2025 results release (Aug 13, 2025): Company IR
Form 10-Q (filed Nov 12, 2025; quarter ended Sep 30, 2025): Company-hosted filing PDF
Q3 2025 results release (Nov 12, 2025): Company IR
LEVEL expansion / LEVEL-2 (Mar 5, 2025): Company announcement (GlobeNewswire)
$25M private placement (Mar 5, 2025): Company IR • details in SEC 10-Q (Mar 31, 2025)
Company IR home: investors.tenaxthera.com

Author Note

Authors: Merlintrader and Jane.

In every report I share things as I personally interpret them, based on raw data from official filings, company communications, and primary verified sources where available. I do not write to promote enthusiasm or pessimism; these are simply my views as a trader, not as a professional analyst. Market sentiment can shift quickly. Official documents and numbers remain what they are. It is possible for me to make mistakes; collecting and cross-checking timelines, clinical data, filings and corporate updates is complex, so inaccuracies may occur. If you spot something off, feel free to let me know and I will correct it. Remember that I am not a professional; do not expect perfection here, only transparency, data, and consistent effort.

Disclaimers / Avvertenze (EN / IT)

EN – Educational-only disclaimer (SEC-style)

This report is for informational and educational purposes only. It does not constitute investment advice, a recommendation, an offer, or a solicitation to buy or sell any financial instrument or security. Nothing in this text should be interpreted as personalized advice or as a research report prepared in accordance with the requirements designed to promote the independence of investment research. Biotech and small/mid-cap equities can be highly volatile and may involve the risk of total capital loss.

Any opinions expressed reflect a personal, non-professional view at the time of writing and may change without notice. Before making any investment decision, you should conduct your own due diligence, verify all data using primary sources (SEC filings, official company communications, and regulator publications), and consider consulting a licensed financial advisor or other qualified professional. Past performance is not indicative of future results.

IT – Avvertenze (stile CONSOB / UE)

I contenuti di questa pagina hanno esclusivamente finalità informative e didattiche e non costituiscono in alcun modo consulenza in materia di investimenti, ricerca o raccomandazioni personalizzate ai sensi della normativa europea (MiFID II) e delle disposizioni CONSOB. Le informazioni fornite non rappresentano un invito, un’offerta o una sollecitazione al pubblico risparmio ad acquistare o vendere strumenti finanziari né intendono sostituire il giudizio autonomo del lettore.

I titoli biotech e, in generale, le small/mid-cap possono essere molto volatili e comportare rischi elevati, incluso il rischio di perdita integrale del capitale investito. Prima di assumere qualsiasi decisione di investimento è opportuno valutare con attenzione la propria situazione finanziaria, gli obiettivi di investimento e la propria propensione al rischio, consultando se necessario un intermediario autorizzato o un consulente finanziario abilitato all’esercizio dell’attività. I dati e le opinioni qui riportati possono contenere errori o imprecisioni e sono soggetti a modifiche; si raccomanda di verificare sempre le informazioni direttamente dalle fonti ufficiali (documenti societari, comunicazioni agli investitori, autorità di vigilanza).

Legal pages: Disclaimer • Terms & Privacy

Navigation

Executive Summary Quick Data Company Overview Pipeline Clinical Data Catalysts Financial Snapshot Ownership / Short / Insider Sentiment Bull vs Bear Key Risks Bottom Line Primary Sources Author Note Disclaimers

Fast Links

Interpretation Guardrails

If a line here sounds “bullish” or “bearish,” treat it as a framework, not a call to action. The stable anchor is what filings and official releases actually say.

Tools & Partners

Finviz
Charts, fundamentals, insider/institutional snapshots, quick market view.

ChartsWatcher
ChartsWatcher is a real-time, next-generation scanner for the US stock market.

Seeking Alpha
News flow, earnings coverage, analysis and investor debate.

Stocktwits
Retail sentiment stream and ticker-based discussions.

Medved Trader
Trading platform and tools (no referral link).

Merlintrader trading Blog
Dashboards, calendars, reports and educational deep dives.

Affiliate note: some links above may be affiliate/referral links. If you use them, it can generate a commission that helps support the site at no extra cost to you.

Support the Project

Donate via PayPal

If the reports help you, consider supporting the work to keep the site free for everyone.

Open PayPal Donation Page

TENX — Milestones (anchored to dated disclosures)

LEVEL expansion / FDA-aligned update (Mar 5, 2025): release
Q2 2025 cash snapshot (as of Jun 30, 2025): company IR and SEC 10-Q
Updated expectations (Q3 2025 corporate update): enrollment completion (230 patients) expected 1H 2026; topline data expected 2H 2026, per Nov 12, 2025 release.

Always verify timelines in the most recent SEC filings and official press releases. Timelines can shift.

Biotech Catalyst Calendar

For the full calendar view (FDA and biotech milestones), use the dedicated page here: https://merlintrader.com/calendario-catalyst/

Scanner for active traders

Try ChartsWatcher free, then unlock 10% OFF with SAVE10

ChartsWatcher is a real-time scanner for momentum traders: fast movers, unusual volume and rotations — so you can focus on the few tickers that matter right now, instead of watching hundreds of charts.

Start with the free version. When you upgrade, use SAVE10 for 10% OFF your first paid period.

Start free – then use SAVE10

No credit card required to start. Apply SAVE10 when upgrading.

Recommended platform

One platform. All your brokers.

Medved Trader connects multiple brokers in one workspace, with pro charts, hotkeys and fast execution — without changing your broker accounts.

A single cockpit for positions, Level II and multi-broker order routing, built for active day & swing traders.

Get 1 Month Free ➔

Multi-broker workflow + customizable layouts in one platform.

Find out how I use AI on Merlintrader: AI, retail and Merlintrader

Disclosure: some of the links in the promotional blocks above are affiliate or referral links. If you choose to subscribe or sign up through them, Merlintrader may receive a small commission or benefit at no extra cost to you.

Authors: Merlintrader, Jane and Gemini

Author's note (English)

In every report I share things as I personally interpret them, based on raw data from official company filings, regulatory documents, conference call transcripts and other primary sources where available. Some parts of the research and structure are supported by AI assistants (Jane and Gemini), which help me organise data, cross-check details and improve charts or visuals. However, any interpretation, opinion and final judgement remain entirely my own as a trader like you, not as a licensed financial advisor or registered analyst. Market sentiment can change quickly, while official documents and numbers remain what they are. It is also possible for me to make mistakes: collecting and cross-checking FDA timelines, clinical data, filings and corporate updates is complex, so inaccuracies may occur. If you spot something that looks off, feel free to let me know and I will correct it. Please do not treat this report as professional investment advice, but as one more piece of information to compare with your own research and the opinion of qualified professionals.

AI usage disclosure (English)

This report has been prepared using a human + AI workflow. Drafting, editing and data organisation are supported by generative AI tools, for example large language models provided by third-party vendors, based on prompts and instructions defined by the author. All sources are publicly available, and the final selection of data, checks, opinions and conclusions is carried out by the author, who remains fully responsible for the content.

Legal disclaimer (English) – please read carefully

This report is provided strictly for informational and educational purposes. It is not and must not be interpreted as investment advice, investment research in a regulatory sense, portfolio management, or a recommendation to buy or sell any security or financial instrument. The author is not a licensed investment advisor, not a registered broker, and not a FINRA/SEC-registered analyst or portfolio manager. Any reference to potential scenarios, price levels or catalysts is purely illustrative and reflects a personal, non-professional view based on publicly available information at the time of writing.

Nothing in this document should be considered a solicitation to the public to invest, nor an invitation to raise capital, nor a promise of profit or of capital protection. Biotech and healthcare stocks in particular can be highly volatile and speculative, especially around clinical and regulatory catalysts. Before making any investment or trading decision, always perform your own due diligence and consider consulting a qualified, regulated financial professional who can evaluate your personal situation, objectives and risk tolerance. Past performance and historical examples do not guarantee future results.

The author may hold, or may have held, long or short positions in some of the securities mentioned in this report, and may open, close or modify such positions without notice. This potential alignment of interests may influence the tone or focus of the analysis. No position held by the author changes the fact that this document is not investment advice and should not be used as such.

I testi completi dei disclaimer e delle condizioni d'uso, in versione sia italiana che inglese, sono disponibili nelle pagine legali ufficiali del sito Merlintrader, indicated here sotto.

If you find these reports useful and want to support the project, you can make a voluntary one-time donation via PayPal or Buy Me a Coffee. It helps cover data, tools and hosting costs so that the content can remain independent and freely accessible.

Tools and research platforms used in this report

Below is a shortlist of tools and platforms that I personally use to follow prices, catalysts, fundamentals and sentiment. Links are provided for transparency and convenience only.

Finviz Elite – advanced stock screener and charting, used for heatmaps, relative performance and technical context.
ChartsWatcher – real-time, next-generation scanner for the US stock market. Used to monitor intraday momentum, volume spikes and colour-coded pattern alerts.
Stocktwits – social stream focused on tickers, used only as a sentiment and activity indicator, not as a source of investment recommendations.
Monica.im – AI assistant used for light reports, drafting and quick research; helps with structuring notes and first-pass analysis alongside the deep-dive work published on Merlintrader.
Medved Trader – professional trading and charting platform used for real-time execution, order-flow and detailed intraday analysis. No affiliate link; mentioned because it is part of the actual trading workflow.
Merlintrader trading Blog – the home for biotech-focused reports, dashboards and educational articles that expand on the ideas mentioned in this document.

Some of the links above are affiliate links. If you decide to subscribe or purchase through them, it may generate a small commission for Merlintrader at no extra cost to you. This helps keep the site online and the reports freely accessible. You are under no obligation to use these links; always choose the solution that best fits your needs and your own evaluation.

Full legal information, risk warnings and terms of use (in both Italian and English) are available on the official Merlintrader legal pages:

Italian version: Disclaimer e avvertenze sui rischi | Condizioni d'uso e informativa sulla privacy

The same pages also include the corresponding English text or an English equivalent of the main legal notices, so that international readers can access the core risk disclosures and terms of use.

Biotech Catalyst Calendar

For a broader, continuously updated view of upcoming biotech catalysts (PDUFA dates, major clinical readouts, regulatory events and key conferences), you can consult the dedicated calendar on Merlintrader.

Open the Biotech Catalyst Calendar

Authors: Merlintrader, Jane and Gemini

Nota dell'autore (Italiano)

In ogni report condivido ciò che vedo e come lo interpreto personalmente, partendo dai dati grezzi di documenti ufficiali, comunicazioni delle società, trascrizioni delle call e altre fonti primarie quando disponibili. Alcune parti del lavoro di ricerca e di impaginazione sono supportate da assistenti IA (Jane e Gemini), che mi aiutano a organizzare i dati, verificare i dettagli e migliorare grafici o elementi visivi. Le valutazioni finali, le opinioni e le conclusioni restano comunque esclusivamente mie, da trader come te, non da consulente finanziario abilitato o analista iscritto ad albi professionali. Il sentiment di mercato può cambiare molto rapidamente, mentre i documenti ufficiali e i numeri restano quelli che sono. È anche possibile che commetta errori: raccogliere e confrontare tempistiche FDA, dati clinici, filing e aggiornamenti societari è un lavoro complesso, quindi qualche imprecisione può sfuggire. Se noti qualcosa che non ti torna, segnalamelo e lo correggerò. Non considerare questo report come consulenza personalizzata, ma come materiale informativo da confrontare con le tue ricerche e con il parere di professionisti qualificati.

Informativa sull'uso di IA generativa (Italiano)

Questo report è stato redatto utilizzando un flusso di lavoro combinato umano + IA. La stesura, la revisione e l'organizzazione dei dati sono supportate da strumenti di intelligenza artificiale generativa, ad esempio modelli linguistici di grandi dimensioni forniti da terze parti, sulla base di istruzioni e controlli definiti dall'autore. Le fonti utilizzate sono pubbliche e la selezione finale delle informazioni, le verifiche, le opinioni e le conclusioni restano sotto la responsabilità esclusiva dell'autore.

Disclaimer legale (Italiano) – leggere con attenzione

Questo report ha finalità esclusivamente informative e didattiche. Non costituisce in alcun modo consulenza in materia di investimenti, ricerca in materia di investimenti in senso regolamentare, gestione di portafogli, né raccomandazione personalizzata o generica ad acquistare, vendere o detenere strumenti finanziari. L'autore non è un consulente finanziario abilitato all'esercizio della professione, non è un promotore finanziario, non è un analista iscritto ad albi professionali e non svolge servizi di investimento ai sensi della normativa vigente.

Qualsiasi riferimento a scenari possibili, livelli di prezzo, probabilità o catalyst ha valore puramente illustrativo e riflette una valutazione personale e non professionale basata su informazioni pubbliche disponibili al momento della stesura. Nulla di quanto scritto rappresenta sollecitazione al pubblico risparmio, offerta al pubblico di prodotti finanziari o promessa di rendimento o di protezione del capitale. In particolare, i titoli biotech e healthcare possono essere estremamente volatili e speculativi, soprattutto in prossimità di eventi clinici o regolatori (PDUFA, letture di trial, ecc.).

L'autore può detenere, o aver detenuto, posizioni long o short su alcuni degli strumenti finanziari menzionati nel report e può aprire, chiudere o modificare tali posizioni senza preavviso. Questa possibile coincidenza di interessi può influenzare il taglio o l'attenzione dell'analisi. La presenza di eventuali posizioni personali non trasforma in alcun modo questo documento in consulenza finanziaria e non deve essere interpretata come tale.

Prima di assumere qualsiasi decisione di investimento o di trading, è indispensabile effettuare le proprie analisi e valutazioni e, se necessario, rivolgersi a un consulente finanziario indipendente e abilitato, in grado di considerare la tua situazione personale, gli obiettivi e la propensione al rischio. Le informazioni riportate possono contenere errori, omissioni o non essere aggiornate; né l'autore né Merlintrader possono essere ritenuti responsabili per eventuali perdite, dirette o indirette, derivanti dall'utilizzo di questo contenuto.

I testi completi dei disclaimer e delle condizioni d'uso, in versione sia italiana sia inglese, sono disponibili nelle pagine legali ufficiali del sito Merlintrader, indicate qui sotto.

Se trovi utili questi report e vuoi sostenere il progetto, puoi fare una donazione volontaria una tantum tramite PayPal o Buy Me a Coffee. È un aiuto concreto per coprire i costi di dati, strumenti e hosting, così i contenuti possono restare indipendenti e liberamente accessibili.

Strumenti e piattaforme di ricerca usati in questo report

Qui sotto trovi una selezione di strumenti e piattaforme che uso personalmente per seguire prezzi, catalyst, fondamentali e sentiment. I link sono forniti solo per trasparenza e comodità del lettore.

Finviz Elite – screener avanzato e piattaforma grafica, usato per heatmap, performance relative e contesto tecnico.
ChartsWatcher – scanner real-time di nuova generazione per il mercato azionario USA. Lo uso per monitorare momentum intraday, picchi di volume e alert cromatici sui pattern.
Stocktwits – flusso social focalizzato sui ticker, usato solo come indicatore di sentiment e attività, non come fonte di raccomandazioni di investimento.
Monica.im – assistente AI usato per report leggeri, drafting e ricerche veloci; utile per strutturare note e prime analisi insieme al lavoro di approfondimento pubblicato su Merlintrader.
Medved Trader – piattaforma professionale di trading e charting usata per esecuzione real-time, order-flow e analisi intraday dettagliata. Nessun affiliate link; è citata perché fa parte del workflow operativo reale.
Merlintrader trading Blog – la casa dei report focalizzati sul biotech, delle dashboard e degli articoli educativi che approfondiscono i temi menzionati in questo documento.

Alcuni dei link sopra indicati sono link affiliati. Se decidi di iscriverti o acquistare tramite uno di essi, Merlintrader potrebbe ricevere una piccola commissione senza costi aggiuntivi per te. Questo aiuta a mantenere il sito online e i report liberamente accessibili. Non hai alcun obbligo di usare questi link: scegli sempre la soluzione che ritieni più adatta alle tue esigenze e alla tua valutazione personale.

Le informazioni legali complete, le avvertenze sui rischi e le condizioni d'uso, in versione sia italiana sia inglese, sono disponibili nelle pagine legali ufficiali di Merlintrader:

Versione italiana: Disclaimer e avvertenze sui rischi | Condizioni d'uso e informativa sulla privacy

Le stesse pagine includono anche il testo corrispondente in inglese o un equivalente inglese delle principali avvertenze legali, così anche i lettori internazionali possono consultare le informazioni essenziali su rischi e condizioni d'uso.

Biotech Catalyst Calendar

Per una visione più ampia e continuamente aggiornata dei prossimi catalyst biotech (date PDUFA, principali letture cliniche, eventi regolatori e conferenze chiave), puoi consultare il calendario dedicato su Merlintrader.

Apri il Biotech Catalyst Calendar

Tenax Therapeutics (NASDAQ: TENX) — clinical-stage cardiopulmonary biotech

Executive Summary

Quick Data (verifiable snapshot)

Company Overview

Pipeline — What matters now vs later

Core program

Earlier-stage / optionality

Clinical Data — What is public and verifiable

Phase 3 LEVEL (TNX-103 oral levosimendan in PH-HFpEF)

Catalysts & What traders will watch

Financial Snapshot (anchored to filings and dated releases)

Ownership / Short Interest / Insider Activity

Sentiment (high-level)

Bull vs Bear Framework (educational, not advice)

Key Risks (plain language)

Bottom Line (what this is, and what it isn’t)

Primary Sources (clickable)

Author Note

Disclaimers / Avvertenze (EN / IT)

Navigation

Fast Links

Interpretation Guardrails

Tools & Partners

Support the Project

TENX — Milestones (anchored to dated disclosures)

Biotech Catalyst Calendar

Try ChartsWatcher free, then unlock 10% OFF with SAVE10

One platform. All your brokers.

Author's note (English)

AI usage disclosure (English)

Legal disclaimer (English) – please read carefully

Tools and research platforms used in this report

Biotech Catalyst Calendar

Nota dell'autore (Italiano)

Informativa sull'uso di IA generativa (Italiano)

Disclaimer legale (Italiano) – leggere con attenzione

Strumenti e piattaforme di ricerca usati in questo report

Biotech Catalyst Calendar